Merck delivers resilient 2025 performance despite global headwinds

Strong performances in its Life Science, Healthcare and Electronics divisions — particularly Process Solutions, Cardiovascular treatments and Semiconductor Materials — powered the company’s results

KIMS Hospitals launches India’s first adaptive deep brain stimulation for Parkinson’s patients

Built on the Percept Platform and enhanced with BrainSense technology, the system can adjust stimulation levels in real time, responding to brain signals without manual intervention

Glenmark bags FDA nod for generic asthma inhaler with 180-day exclusivity

Eris Lifesciences partnership with Natco Pharma for Semaglutide launch in India

The product will target Type 2 diabetes management aligning with unmet needs in India’s expanding metabolic care landscape

Novo Nordisk’s "Triple G" drug UBT251 triggers nearly 20% weight loss in 24 weeks

UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies

BriaCell spins off sCD80 cancer therapy to BriaPro in strategic deal

Merck restructures Human Health division for future growth

Merck is currently conducting approximately 80 Phase 3 studies, and the company expects more than 20 new growth drivers over next several years, almost all with blockbuster potential

Torrent Pharmaceuticals posts Rs. 577 Cr Q3 profit; nine-month earnings jump to Rs. 1,725 Cr

NATCO receives CDSCO approval for Semaglutide in India

Semaglutide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus

Novo Medi Sciences launches ‘G.A.U.R.I.’ to drive immunization for underprivileged girls

Novo Medi Sciences aims to reach millions nationwide and provide NEXIPOX PLUS vaccination against chickenpox to thousands of underprivileged girl children